Coronavirus Disease 19 (COVID-19) Guidelines February 2020 V1.1
Coronavirus Disease 19 (COVID-19) Guidelines February 2020 V1.1
Version 1.0 was written and published on January 10th 2020.
Version 1.1
- Updated the name of the virus and the disease name.
- Updated the case definition
- Added (Management of exposure to COVID-19 in healthcare facilities)
- Added (The risk communication)
- Updated the designated hospitals list
- Updated the reporting form and the visual triage checklist form.
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
Abstract
The coronavirus disease 2019 (COVID-19) virus is spreading rapidly, and scientists are endeavoring to discover drugs for its efficacious treatment in China. Chloroquine phosphate, an old drug for treatment of malaria, is shown to have apparent efficacy and acceptable safety against COVID-19 associated pneumonia in multicenter clinical trials conducted in China. The drug is recommended to be included in the next version of the Guidelines for the Prevention, Diagnosis, and Treatment of Pneumonia Caused by COVID-19 issued by the National Health Commission of the People's Republic of China for treatment of COVID-19 infection in larger populations in the future.
Novel Corona Virus (2019-nCoV) Infection Guidelines (lecture)
Novel Corona Virus (2019-nCoV) Infection Guidelines (lecture)
Clinical management of severe acute respiratory infection when Novel coronavirus (2019-nCoV) infection is suspected: Interim Guidance
Clinical management of severe acute respiratory infection when Novel coronavirus (2019-nCoV) infection is suspected: Interim Guidance. 28 January 2020
Novel Corona Virus (2019-nCoV) Infection Guidelines V1.0 January
The MOH Novel Corona Virus (2019-nCoV) Infection Guidelines, V1.0 January
The MOH Interim Guide to Novel Coronavirus Infection 2019-nCoV
File name: Interim-Guide-to-Novel-Coronavirus-Infection-2019-nCoV.pdf
Manual of Infection Prevention & Control in Dental Settings (2018)
The new published version of the Manual of Infection Prevention & Control in Dental Settings. Second Edition, 2018
File name: Manual-of-Infection-Prevention-and-Control-in-Dental-Settings-2018.pdf
Antibiotic Guidelines in NICUs Improve Prescription Practices for Vulnerable Infants
Management of health care workers who had contacts with patients with MERS-CoV infection
Health care facilities should trace all health care workers who had protected or unprotected contacts with patients with suspected, probable, or confirmed MERS-CoV infection.
a) Testing (Nasopharyngeal swabs) for MERS-CoV is recommended even if asymptomatic.
b) Testing should not be done before 24 hours of exposure.
c) Single test only required unless symptomatic where repeated testing is required.
d) Contact should be off work until the test is reported as negative.
a) Testing for MERS-CoV is not recommended if asymptomatic.
b) Continue to work in the hospital unless they become symptomatic.
a) Testing for MERS-CoV is not recommended if asymptomatic.
b) Continue to work in the hospital unless they become symptomatic.
a) Patients can be exposed to MERS patients during pre-diagnosis phase or due to failure of recommended isolation precautions.
b) Testing for MERS-CoV should be done 24 hours or more after the last exposure.
c) Such patients should be followed for symptoms for 14 days after exposure with testing to be done upon development of symptoms suggestive of MERS.
The infection control unit of the facility or equivalent there of should trace all contacts within the HCF and proactively call by phone all contacts to assess their health daily for a total of 14 days. Contacts should also be instructed to report immediately to the Staff Health Clinic or Emergency Room if they develop upper or lower respiratory illness.
a) Investigation should be under guidance of Infection Prevention and Control Unit of the hospital, Regional Command and Control Center and Central Command and Control Center.
b) More testing of asymptomatic HCW may be required.
c) Cohorting or closure of units should be in consultation with the regional command and control center.
d) Surge plan to be in place in case of large outbreak.